BACKGROUND: Bronchoalveolar lavage (BAL) fluid prostaglandin D₂(PGD₂) levels are increased in patients with severe, poorly controlled asthma in association with epithelial mast cells (MCs). PGD₂, which is generated by hematopoietic prostaglandin D synthase (HPGDS), acts on 3 G protein-coupled receptors, including chemoattractant receptor-homologous molecule expressed on TH2 lymphocytes (CRTH2) and PGD₂ receptor 1 (DP1). However, much remains to be understood regarding the presence and activation of these pathway elements in asthmatic patients. OBJECTIVE: We sought to compare the expression and activation of PGD₂ pathway elements in bronchoscopically obtained samples from healthy control subjects and asthmatic patients across a range of disease severity and control, as well as in relation to TH2 pathway elements. METHODS: Epithelial cells and BAL fluid were evaluated for HPGDS (quantitative real-time PCR/immunohistochemistry [IHC]) and PGD₂ (ELISA/liquid chromatography mass spectrometry) in relation to levels of MC proteases. Expression of the 2 inflammatory cell receptors DP1 and CRTH2 was evaluated on luminal cells. These PGD₂ pathway markers were then compared with asthma severity, level of control, and markers of TH2 inflammation (blood eosinophils and fraction of exhaled nitric oxide). RESULTS: Confirming previous results, BAL fluid PGD₂ levels were highest in patients with severe asthma (overall P = .0001). Epithelial cell compartment HPGDS mRNA and IHC values differed among groups (P = .008 and P < .0001, respectively) and correlated with MC protease mRNA. CRTH2 mRNA and IHC values were highest in patients with severe asthma (P = .001 and P = .0001, respectively). Asthma exacerbations, poor asthma control, and TH2 inflammatory markers were associated with higher PGD₂, HPGDS, and CRTH2 levels. CONCLUSION: The current study identifies coordinated upregulation of the PGD₂ pathway in patients with severe, poorly controlled, TH2-high asthma despite corticosteroid use.
BACKGROUND: Bronchoalveolar lavage (BAL) fluid prostaglandin D₂(PGD₂) levels are increased in patients with severe, poorly controlled asthma in association with epithelial mast cells (MCs). PGD₂, which is generated by hematopoietic prostaglandin D synthase (HPGDS), acts on 3 G protein-coupled receptors, including chemoattractant receptor-homologous molecule expressed on TH2 lymphocytes (CRTH2) and PGD₂ receptor 1 (DP1). However, much remains to be understood regarding the presence and activation of these pathway elements in asthmatic patients. OBJECTIVE: We sought to compare the expression and activation of PGD₂ pathway elements in bronchoscopically obtained samples from healthy control subjects and asthmatic patients across a range of disease severity and control, as well as in relation to TH2 pathway elements. METHODS: Epithelial cells and BAL fluid were evaluated for HPGDS (quantitative real-time PCR/immunohistochemistry [IHC]) and PGD₂ (ELISA/liquid chromatography mass spectrometry) in relation to levels of MC proteases. Expression of the 2 inflammatory cell receptors DP1 and CRTH2 was evaluated on luminal cells. These PGD₂ pathway markers were then compared with asthma severity, level of control, and markers of TH2 inflammation (blood eosinophils and fraction of exhaled nitric oxide). RESULTS: Confirming previous results, BAL fluid PGD₂ levels were highest in patients with severe asthma (overall P = .0001). Epithelial cell compartment HPGDS mRNA and IHC values differed among groups (P = .008 and P < .0001, respectively) and correlated with MC protease mRNA. CRTH2 mRNA and IHC values were highest in patients with severe asthma (P = .001 and P = .0001, respectively). Asthma exacerbations, poor asthma control, and TH2 inflammatory markers were associated with higher PGD₂, HPGDS, and CRTH2 levels. CONCLUSION: The current study identifies coordinated upregulation of the PGD₂ pathway in patients with severe, poorly controlled, TH2-high asthma despite corticosteroid use.
Authors: Ryan H Dougherty; Sukhvinder S Sidhu; Kavita Raman; Margaret Solon; Owen D Solberg; George H Caughey; Prescott G Woodruff; John V Fahy Journal: J Allergy Clin Immunol Date: 2010-05 Impact factor: 10.793
Authors: J Pablo Abonia; Carine Blanchard; Bridget Buckmeier Butz; Heather F Rainey; Margaret H Collins; Keith Stringer; Philip E Putnam; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2010-06-09 Impact factor: 10.793
Authors: Karin J Stebbins; Alex R Broadhead; Lucia D Correa; Jill M Scott; Yen P Truong; Brian A Stearns; John H Hutchinson; Peppi Prasit; Jilly F Evans; Daniel S Lorrain Journal: Eur J Pharmacol Date: 2010-05-04 Impact factor: 4.432
Authors: Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2007-02 Impact factor: 10.793
Authors: Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews Journal: N Engl J Med Date: 2011-08-03 Impact factor: 91.245
Authors: Sally E Wenzel; Silvana Balzar; Elizabeth Ampleford; Gregory A Hawkins; William W Busse; William J Calhoun; Mario Castro; K Fan Chung; Serpil Erzurum; Benjamin Gaston; Elliot Israel; W Gerald Teague; Douglas Curran-Everett; Deborah A Meyers; Eugene R Bleecker Journal: Am J Respir Crit Care Med Date: 2006-12-14 Impact factor: 21.405
Authors: Silvana Balzar; Merritt L Fajt; Suzy A A Comhair; Serpil C Erzurum; Eugene Bleecker; William W Busse; Mario Castro; Benjamin Gaston; Elliot Israel; Lawrence B Schwartz; Douglas Curran-Everett; Charity G Moore; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2010-09-02 Impact factor: 21.405
Authors: K Chibana; J B Trudeau; A T Mustovich; A T Mustovitch; H Hu; J Zhao; S Balzar; H W Chu; S E Wenzel Journal: Clin Exp Allergy Date: 2008-04-01 Impact factor: 5.018
Authors: Wendy C Moore; Michael D Evans; Eugene R Bleecker; William W Busse; William J Calhoun; Mario Castro; Kian Fan Chung; Serpil C Erzurum; Douglas Curran-Everett; Raed A Dweik; Benjamin Gaston; Mark Hew; Elliot Israel; Martin L Mayse; Rodolfo M Pascual; Stephen P Peters; Lori Silveira; Sally E Wenzel; Nizar N Jarjour Journal: J Allergy Clin Immunol Date: 2011-04-15 Impact factor: 10.793
Authors: Min Xie; Anthony T Mustovich; Yi Jiang; John B Trudeau; Anuradha Ray; Prabir Ray; Haizhen Hu; Fernando Holguin; Bruce Freeman; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2014-10-11 Impact factor: 10.793
Authors: Xiuxia Zhou; Carol L Kinlough; Rebecca P Hughey; Mingzhu Jin; Hideki Inoue; Emily Etling; Brian D Modena; Naftali Kaminski; Eugene R Bleecker; Deborah A Meyers; Nizar N Jarjour; John B Trudeau; Fernando Holguin; Anuradha Ray; Sally E Wenzel Journal: JCI Insight Date: 2019-03-07
Authors: Tao Huang; Meredith Hazen; Yonglei Shang; Meijuan Zhou; Xiumin Wu; Donghong Yan; Zhonghua Lin; Margaret Solon; Elizabeth Luis; Hai Ngu; Yongchang Shi; Arna Katewa; David F Choy; Nandhini Ramamoorthi; Erick R Castellanos; Mercedesz Balazs; Min Xu; Wyne P Lee; Marissa L Matsumoto; Jian Payandeh; Joseph R Arron; Jo-Anne Hongo; Jianyong Wang; Isidro Hötzel; Cary D Austin; Karin Reif Journal: JCI Insight Date: 2016-05-19